Frequently Asked Questions:
The global pharma R&D outsourcing market was valued at USD 72.1 Billion in 2022.
The pharma R&D outsourcing market is expected to grow at a CAGR of 9.56% between 2023 and 2030, reaching USD 136.6 Billion in 2030.
The clinical category had a significant proportion of roughly 64.13%.
Large companies segment is leading the market demand.
The biologics segment will likely exhibit the fastest CAGR during the forecast period.
North America is the most important market for pharmaceutical R&D outsourcing, accounting for a sizable portion of the global market.
The top players include Advanced Clinical, BioAnalytix, Asymchem and Alcam. Other major players include Curia Global, ChemPartner, CMED, Criterium and Cromos Pharma.
Increased use of cloud computing and related software platforms in research and development, as well as Al’s appearance in drug discovery and development, are the major market drivers.
Concerns over intellectual property, as well as the high cost and low success rate of pharmaceutical research and development are the major market restraints.
enture capitalist investments in the Life Sciences/Blotch Industry are increasing, as is access to specialized knowledge the major opportunity in the pharma R&D outsourcing industry.